MS and Demyelinating Disorders

Patients who started therapy immediately after the initial attack had a relapse risk of just 11% at 2 years and 20% at 6 and 8 years, compared to much higher rates (41% at 2 years, 56% at 8 years) in those who delayed therapy until a second attack.

At the 2024 ECTRIMS Congress, the associate professor of clinical neurology at Keck School of Medicine of USC talked about recent research that highlights the preclinical phase of multiple sclerosis. [WATCH TIME: 9 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® will provide in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 10, 2024.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry provided a clinical overview of preclinical research identifying a new receptor for nerve growth factor that plays an important role in pain signaling. [WATCH TIME: 4 minutes]

Between those infected and uninfected with COVID-19, investigators observed no differences in symptom trajectories, assessed through SymptoMScreen.

The professor in the department of clinical pharmacy and neurology at the University of Colorado reflected on the significance of peer recognition, the evolution of MS clinics, and the importance of staying engaged in professional contributions. [WATCH TIME: 6 minutes]

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about how modern advances research have helped transition the understanding of multiple sclerosis from fixed phenotypes to a dynamic spectrum.

The postdoctoral research assistant at Charité University Berlin discussed advances in diagnostic criteria and 7-Tesla MRI imaging, highlighting a previously overlooked overlap between anti-N-methyl-D-aspartate receptor encephalitis and multiple sclerosis. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Ultimately, the biomarkers' temporal patterns may help differentiate attacks from remission, with sGFAP being particularly useful in distinguishing genuine attacks from pseudoattacks.

Catch up on any of the neurology news headlines you may have missed over the course of December 2024, compiled all into one place by the NeurologyLive® team.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched expert-led video series that appeared on the website in 2024.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 3, 2024.

A feature on NeurologyLive®, IJMSC Insights offers a look at the data around employment among people with MS.

Imlifidase-IVIg treatment led to faster disability improvement (3 weeks) and earlier independent walking (6 weeks) compared to IVIg alone.

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about the shift in multiple sclerosis diagnostics from rigid classification systems to a dynamic, spectrum-based approach focused on biological phenotyping. [WATCH TIME: 5 minutes]

As part of NeurologyLive®'s Year in Review, we've compiled the most-listened episodes of our biweekly podcast, Mind Moments®.

As part of NeurologyLive®'s Year in Review, we've compiled the most-watched interview clips that appeared on the website in 2024.

As part of NeurologyLive®'s Year in Review, take a look at our most-read news in multiple sclerosis in 2024.

As part of NeurologyLive®'s Year in Review, we've compiled the top coverage stories from 2024 across a variety of different neurological conferences the team either attended or covered virtually.

As part of NeurologyLive®'s Year in Review, we've compiled the most-read feature-length stories that appeared on the website in 2024.

With new revisions of the MS diagnostic criteria being made, clinicians highlighted key updates and the broader implications it has for diagnosis, treatment, and healthcare practices worldwide.

The complement system is critical in immune defense and tissue homeostasis, but its dysregulation can contribute to autoimmune neurological disorders and neurodegenerative diseases like Alzheimer, ALS, and multiple sclerosis.

IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

The professor of neurology at University of Florence talked about a study presented at ECTRIMS 2024 that validated definitions of progression independent of relapse activity in early relapsing MS. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending December 21, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 20, 2024.